Danaher's Leica Biosystems Completes Acquisition of StatLab Medical Products

Key Facts

1Leica Biosystems, a Danaher company, has completed its acquisition of StatLab Medical Products.

2The acquisition aims to enhance cancer diagnostic solutions and optimize anatomic pathology workflows.

Leica Biosystems, a Danaher company, has completed its acquisition of StatLab Medical Products. PR Newswire reported that the acquisition aims to enhance cancer diagnostic solutions and optimize anatomic pathology workflows, enabling laboratories to move from sample to answer with increased speed and precision.

Danaher's stock, DHR, closed at $224.49 on September 25, 2026, after reaching a day high of $224.9 and a low of $221.6. This strategic move is intended to strengthen the company's position in the diagnostics market and expand its histology workflow capabilities.